Method of detecting and monitoring prostate and ovarian cancers
OwnerEleftherios Diamandisinventor
Life of this patent
Estimating the term…
Abstract
A method for the diagnosis, prognosis, and monitoring of ovarian or prostate cancer in a subject by detecting hK11 in a sample from the subject, preferably a serum sample. hK11 may be measured using a reagent that detects or binds to hK11 preferably antibodies specifically reactive with hK11 or a part thereof. Imaging methods for tumors associated with hK11 are also described using an agent that binds to hK11 which has a label for imaging the tumor.
Claims27
A method for screening a subject for ovarian or prostate cancer comprising (a) obtaining a biological sample from a subject;
- (b) detecting the amount of hK11in said sample;
- and (c) comparing said amount of hK11 detected to a predetermined standard, where detection of a level of hK11 that is different than that of a predetermined standard indicates disease.
A method of monitoring the stage of prostate or ovarian cancer in a subject suffering from prostate or ovarian cancer which comprises (a) identifying a subject suffering from prostate or ovarian cancer;
- (b) determining hK11 levels in a biological sample from the subject to establish a baseline hK11 level for the subject;
- (c) measuring hK11 levels in biological samples of the same type from the subject at subsequent time periods;
- and (d) comparing the measured hK11 levels with the baseline hK11 levels, wherein an increase in measured hK11 levels in the subject versus baseline hK11 levels in the subject is associated with a cancer which is progressing and a decrease in measured hK11 levels versus baseline hK11 levels is associated with a cancer which is regressing or in remission.
A method for detecting the presence of prostate or ovarian cancer in a subject suspected of suffering from prostate or ovarian cancer which comprises (a) measuring transcription levels of hK11 in a biological sample from a subject suspected of suffering from prostate or ovarian cancer;
- and (b) comparing the measured transcription levels of hK11 with hK11 transcription levels in a biological sample from a predetermined standard.
A method for detecting prostate or ovarian carcinoma in a subject by measuring hK11 in a sample from the subject comprising:
- (a) contacting a biological sample from the subject with an antibody specific for hK11 which is directly or indirectly labelled with a detectable substance;
- (b) detecting the detectable substance to measure hK11 in the sample;
- (c) comparing the measured level of hK11 to levels obtained for a predetermined standard.
A method for detecting prostate or ovarian cancer in a subject comprising:
- (a) reacting a biological sample from the subject with a first antibody specific for hK11 which is directly or indirectly labeled with a detectable substance, and a second antibody specific for hK11 which is immobilized;
- (b) separating the first antibody from the second antibody to provide a first antibody phase and a second antibody phase;
- (c) detecting the detectable substance in the first or second antibody phase thereby measuring hK11 in the biological sample;
- and
- (d) comparing the measured hK11 with levels measured for a predetermined standard.
A method for detecting prostate or ovarian cancer comprising (a) reacting a biological sample from a subject with an antibody specific for hK11 which is directly or indirectly labelled with an enzyme;
- (b) adding a substrate for the enzyme wherein the substrate is selected so that the substrate, or a reaction product of the enzyme and substrate forms fluorescent complexes;
- (c) quantitating hK11 in the biological sample by measuring fluorescence of the fluorescent complexes;
- and (d) comparing the quantitated levels to levels obtained for a predetermined standard.
A method for imaging a tumor associated with hK11 comprising:
- (a) incubating the tumor with an agent that binds to hK11 for a sufficient period of time to permit the agent to bind to hK11associated with the tumor, where the agent carries a label for imaging the tumor;
- and
- (b) detecting the presence of the label localized to the tumor.
Dependencies are inferred from the claim text.